Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Sponsor: Bruce Robinson, MD
ClinicalTrials ID:NCT07010692
This clinical trial evaluates the use of thulium and erbium non-ablative fractional lasers, combined with tirbanibulin ointment, to treat biopsy-confirmed squamous and basal cell carcinomas. Eligible participants have not received prior treatments. The intervention involves laser treatment followed by a 5-night application of tirbanibulin ointment for advanced cases, aiming to reduce surgical needs and improve cosmetic outcomes.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Eligibility Criteria
Inclusion Criteria
biopsy confirmed squamous and/or basal cell carcinoma not previously treated by another method.
Exclusion Criteria
- Cannot be pregnant at the time of treatment
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Bruce Robinson, MD | 10022 | New York | New York |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.